BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

UTHR

UNITED THERAPEUTICS Corp
Nasdaq · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

Revenue, quarterly

$783M−1.9% year on year
$1B$500M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 5 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

86.1%−2.8 pp year on year
95%92.5%90%87.5%85%
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 5 Aug 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$1.80B+13.2% year on year
$2B$1B$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 5 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

$1.09B+2.1% year on year
$1.5B$1B$500M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 5 Aug 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty